Clinical trials: Withdrawal
Acute-onset Herpes Zoster Pain
Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster (Shingles) Pain
Study 2022-HZ-011 will utilize a randomized withdrawal (RW), double-blind, placebo controlled design in which the PK and safety of CNTX 2022 (40% anhydrous lidocaine gel) will be evaluated in subjects with acute-onset herpes…
- Trial name
- NCT02679339
- Testing
- CNTX-2022 (lidocaine gel, 40%)
- Where
- Australia
- Volunteers
- 1 people
- Sponsor
- Centrexion Therapeutics
Rheumatoid Arthritis
A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis
Thus study will test an experimental drug called Z-102 (combination of prednisolone and dipyridamole) to treat patients with moderate to severe rheumatoid arthritis.
- Trial name
- Synergy (NCT01369745)
- Testing
- Prednisolone, dipyridamole, Prednisone
- Where
- United States
- Volunteers
- 294 people
- Sponsor
- Zalicus
Juvenile Idiopathic Arthritis
A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis
This 3-part study evaluated the efficacy and safety of tocilizumab in patients with active polyarticular-course juvenile idiopathic arthritis who have an inadequate response to, or were intolerant of methotrexate.
- Trial name
- NCT00988221
- Testing
- Tocilizumab
- Where
- 69 sites in United States, Argentina and 13 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Fibromyalgia
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.
- Trial name
- FORWARD (NCT07398417)
- Testing
- AXS-14 (Esreboxetine)
- Where
- 53 sites in United States
- Volunteers
- 620 people
- Sponsor
- Axsome Therapeutics, Inc.
Rheumatoid Arthritis
Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis
This study is designed to evaluate the efficacy and safety of tofacitinib modified release formulation (11mg QD) versus tofacitinib modified release formulation plus continued methotrexate treatment in subjects with moderate to…
- Trial name
- NCT02831855
- Testing
- CP-690,550, Methotrexate
- Where
- 136 sites in United States, Australia and 14 more
- Volunteers
- 694 people
- Sponsor
- Pfizer
Opioid Withdrawal
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
This Phase 1b/2 inpatient study assessed the safety, pharmacokinetics, and early signs of efficacy of escalating doses of BXCL501 versus placebo following discontinuation of morphine maintenance.
- Trial name
- NCT04470050
- Testing
- Dexmedetomidine
- Where
- 3 sites in United States
- Volunteers
- 225 people
- Sponsor
- BioXcel Therapeutics Inc
Alzheimer Disease
Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients
A two-year safety study of simufilam (PTI-125) 100 mg oral tablets twice daily for participants of the previous simufilam studies as wells as additional new mild-to-moderate Alzheimer's disease subjects for a total of 200…
- Trial name
- PTI-125 (NCT04388254)
- Testing
- Simufilam 100 mg oral tablet
- Where
- 17 sites in United States, Canada
- Volunteers
- 220 people
- Sponsor
- Cassava Sciences, Inc.
Acromegaly
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)
A Phase 2 double-blind, placebo-controlled, randomized withdrawal study is designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are responders to…
- Trial name
- NCT03792555
- Testing
- Paltusotine
- Where
- 11 sites in United States, Brazil and 6 more
- Volunteers
- 13 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Diabetes Mellitus, Type 1
Diabetes AutoimmunitY Withdrawn in Established Patients (DAY)
The study is a prospective, randomized, double-blind, placebo-controlled, multicenter trial in subjects with established T1D.
- Trial name
- DAY (NCT03794960)
- Testing
- TOL-3021
- Sponsor
- Tolerion, Inc.
NLRC4-MAS, XIAP Deficiency
Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency
This is a Phase 3 study to assess the safety and efficacy of Tadekinig alfa in patients with monogenic, interleukin-18 (IL 18) driven autoinflammation due to Nucleotide-binding oligomerization domain, leucine-rich repeat and…
- Trial name
- NCT03113760
- Testing
- Tadekinig alfa, 0.9% sodium chloride
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 15 people
- Sponsor
- AB2 Bio Ltd.
Arthritis, Rheumatoid
A Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Rheumatoid Arthritis Patients
The purpose of this study is to determine if GSK706769 can maintain clinical remission established by Enbrel after withdrawal of Enbrel in rheumatoid arthritis patients.
- Trial name
- NCT00979771
- Testing
- GSK706769
- Where
- Netherlands
- Sponsor
- GlaxoSmithKline
Anxiety Disorders
Safety and Efficacy Maintenance Study of Quetiapine SR to Treat GAD Patients.
The primary objective of this study is to evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to an anxiety event in patients with generalised anxiety disorder (GAD).
- Trial name
- PLATINUM (NCT00314210)
- Testing
- Quetiapine SR
- Where
- 114 sites in United States, Australia and 9 more
- Volunteers
- 575 people
- Sponsor
- AstraZeneca
Irritable Bowel Syndrome
DARWIN Study: A Randomization/Withdrawal Efficacy Study of Dexloxiglumide in Constipation-Predominant Irritable Bowel Syndrome (C-IBS)
Irritable Bowel Syndrome (IBS) is the most commonly identified functional gastrointestinal disorder, affecting 10-20% of the population in the Western world, seen predominantly in females and with a negative impact on quality of…
- Trial name
- NCT00220090
- Testing
- dexloxiglumide
- Where
- United Kingdom
- Sponsor
- Rottapharm
Myocardial Infarction, Coronary Disease
A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)
The purpose of this research study is to obtain experience in the use of fondaparinux (Arixtra) as compared to heparin when administered to patients who undergo percutaneous coronary intervention (PCI).
- Trial name
- NCT00060554
- Testing
- fondaparinux sodium, heparin, percutaneous coronary intervention (PCI)
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 300 people
- Sponsor
- Schering-Plough
Chronic Genotype 1 Hepatitis C Virus Infection
Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)
This study will evaluate the safety, tolerability, and efficacy of vaniprevir when administered concomitantly with pegylated interferon (peg-IFN) and ribavirin (RBV) to treat treatment-naive genotype 1 hepatitis C virus…
- Trial name
- NCT00895882
- Testing
- vaniprevir (MK7009), Comparator: vaniprevir (MK7009), Comparator: Pegylated Interferon (peg-IFN) alfa-2a
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Neoplasms
Impact of Experience on Results With the Third Eye Retroscope
The Third Eye Retroscope is a device that can be used with a colonoscope to improve the ability of a physician to see areas of the colon that may be hidden from the view of the colonoscope.
- Trial name
- NCT00969124
- Testing
- Third Eye Retroscope
- Where
- 9 sites in United States
- Volunteers
- 328 people, healthy volunteers welcome
- Sponsor
- Avantis Medical Systems
Opioid Dependency
A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction
Probuphine (buprenorphine implant) is an implant placed just below the skin containing buprenorphine (BPN). BPN is an approved treatment for opioid dependence. This study will confirm the efficacy of Probuphine vs.
- Trial name
- NCT01114308
- Testing
- Probuphine (buprenorphine implant), Buprenorphine
- Where
- 20 sites in United States
- Volunteers
- 287 people
- Sponsor
- Titan Pharmaceuticals
Asthma
Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma
This study will evaluate the safety and efficacy of QAX576 against asthma attacks in adults with moderate persistent allergic asthma
- Trial name
- NCT00598104
- Testing
- QAX576
- Sponsor
- Novartis
Hyperphosphatemia
A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
This Phase 3, 26-week, open label study with a 12-week, placebo-controlled, randomized withdrawal period followed by an open label long term safety extension will evaluate the safety and efficacy of tenapanor to treat…
- Trial name
- NCT03427125
- Testing
- Tenapanor, Sevelamer Carbonate
- Where
- 2 sites in United States
- Volunteers
- 1,559 people
- Sponsor
- Ardelyx
Dermatitis, Dermatitis, Atopic
Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis.
- Conditions
- Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases
- Trial name
- NCT03627767
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg
- Where
- 235 sites in United States, Argentina and 19 more
- Volunteers
- 1,235 people
- Sponsor
- Pfizer